Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
483.96
-10.65 (-2.15%)
Nov 14, 2024, 4:00 PM EST - Market closed
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 5,400 employees as of December 31, 2023. The number of employees increased by 600 or 12.50% compared to the previous year.
Employees
5,400
Change (1Y)
600
Growth (1Y)
12.50%
Revenue / Employee
$1,967,741
Profits / Employee
-$88,852
Market Cap
124.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Sanofi | 86,088 |
Danaher | 63,000 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
Amgen | 26,700 |
VRTX News
- 9 days ago - Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It - Seeking Alpha
- 10 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength - Reuters
- 10 days ago - Vertex Reports Third Quarter 2024 Financial Results - Business Wire
- 16 days ago - Vertex to Participate in Upcoming November Investor Conferences - Business Wire
- 20 days ago - Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress - Business Wire
- 25 days ago - Vertex Pharmaceuticals: A Long-Term Growth Monster - Seeking Alpha
- 27 days ago - Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting - Business Wire